OrthoTrophix, Inc.

1:45 PM - 2:00 PM (PDT), Tuesday, June 14, 2022
OrthoTrophix has demonstrated excellent safety, robust improvements of knee function and pain, as well as evidence of disease modification in a broad range of knee osteoarthritis patients in Phase 2 clinical studies of the company's lead therapeutic drug candidate. The overall clinical data strongly suggest delaying or even arresting of the advancement of knee OA, which leads to delay and/or elimination of the needs for knee replacement surgeries. OrthoTrophix controls all relevant IPs and seek corporate partnering and financing on the late stage development of this project.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
TPX-100, a Disease Modifying Osteoarthritis Drug
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President and CEO
OrthoTrophix, Inc.